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Abstract 
 
 
DNP FINAL REPORT: BUILDING A COMPREHENSIVE GUIDELINE TO IMPROVE THE 
TREATMENT OF INFANTS WITH NEONATAL ABSTINENCE SYNDROME:  ADDING 
NON-PHARMACOLOGICAL INTERVENTIONS TO A MORPHINE PROTOCOL 
 
Cyndi B. Kelley, MSN, RNC-LRN 
DNP Project Team Chair: Ellen Fineout-Overholt, PhD, RN, FNAP, FAAN 
The University of Texas at Tyler 
May 2020 
 
Background: The incidence of Neonatal Abstinence Syndrome (NAS) has increased nationally; 
however, only 55% of NICUs indicated having a written NAS treatment plan as recommended 
by the American Association of Pediatrics. Current practice included symptom management via 
morphine only; however, non-pharmacological interventions were not routinely delivered.   
Purpose: The purpose of this project was to standardize and improve the care provided to 
patients with NAS.   
Methods: A systematic search was conducted using keywords and subject headings from the 
PICOT question. Retrieved synthesized evidence suggested that adding breastfeeding and 
rooming-in as first line treatment options reduced the length of hospital stay and medication 
treatment. An interprofessional council developed and implemented a comprehensive treatment 
guideline featuring education on addiction, trauma informed care, evidence-based NAS treatment 
options, and Finnegan scoring.   
Results: Post-education knowledge assessment scores were 100 percent.  Hospital length of stay 
was reduced from 27 (2017) to 17 days (2019) and length of morphine treatment was reduced 
from 34 (2017) to 20 days (2019).  Associated hospital all NAS cases costs dropped from 
vi 
 
$499,709 pre-intervention to $192,573 post-intervention.  The guideline is now the standard plan 
of care to ensure that all NAS patients receive best practice. 
  1 
Chapter 1: Development of the Leadership Question and Problem Identification (EBP 
Process Steps, 0, 1, & 2) 
Background and Significance 
In December 2016, a young couple welcomed their newborn daughter to the world.  She 
was a beautiful baby with dark hair and a stunning smile.  Unfortunately, Gracelynn tested 
positive for opiates because of her mother’s heroin use during pregnancy.  Within forty hours of 
birth, Gracelynn experienced blood sugar instability, intermittent high pitch cry, tremors, nasal 
congestion, and increased muscle tone.  During this time, Gracelynn received controlled opioid 
doses to manage painful withdrawal symptoms; she was experiencing a condition called 
Neonatal Abstinence Syndrome (NAS).  When they learned of Gracelyn’s condition, Child 
Protective Services (CPS) removed custody of Gracelynn from her mother and father and 
restricted parental visitation to supervised visits, only in the presence of a CPS caseworker.  
Gracelynn’s grandmother could visit without restrictions.  Gracelynn spent many days alone in 
her hospital room.  The lack of interactions, including holding, eye contact, talking, and touch, 
increased her irritability, leading to delays in weaning or escalations in medication dosage.  
Ultimately, Gracelynn’s hospitalization lasted a total of 63 days, well beyond the average 16-day 
length of stay (LOS) for NAS (Patrick et al., 2012). 
The Center for Behavioral Health Statistics and Quality’s 2014 national survey on drug 
use and health (2015) indicated 44.5% of females, 12 years old or older, reported illicit drug use 
in their lifetime.  The incidence of non-medical use of opioid pain relievers is highest in women 
18 to 25 years old.  The current opioid crisis raises significant concerns in that as substance use 
issues in women of childbearing age continue to multiply, the number of NAS cases will follow.  
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Drug overdoses come in second to car accidents as the number two cause of injury/death in the 
US (Leonard, 2016; Chopra & Marasa, 2017).  21.5 million Americans suffer from substance use 
disorders, including 1.9 million using prescribed opioids and nearly 600,000 using heroin 
(Centers for Disease Control and Prevention, 2016; Chopra & Marasa, 2017).  Heroin-related 
deaths tripled between 2010 and 2013, while opioid-related deaths among women increased by 
400% between 1999 and 2010 (Chopra & Marasa, 2017).  Over the past decade, the use of 
opiates during pregnancy has significantly increased and has become a compelling public health 
concern (Stover & Davis, 2015).  Prescription opioid use in pregnancy positively correlates with 
neonatal complications; opiate use can lead to intrauterine growth restriction, placental 
abruption, preterm birth, oligohydramnios, stillbirth, and maternal death.  Adverse infant 
neurodevelopmental outcomes also have been shown to result from maternal drug use during 
pregnancy (Stover & Davis, 2015). 
NAS is a constellation of behavioral and physiological signs and symptoms resulting 
from exposure in utero to maternal drug use of opioids, stimulants, depressants, cigarettes, 
serotonin reuptake inhibitors (SSRI), or any combination thereof (MacMullen, Dulski, & 
Blobaum, 2014: Chopra & Marasa, 2017).  Fifty-five to 94% of infants exposed to drugs in utero 
will develop NAS (Minnesota Hospital Association, 2013).  Most NAS symptoms manifest in 
the central and autonomic nervous systems as well as the gastrointestinal tract (Jensen, 2014).  
Symptoms can include, but are not limited to, hyperirritability, tachypnea, poor sleep or feeding 
patterns, and tremors (MacMullen, Dulski, & Blobaum, 2014).  The onset of symptoms and 
intensity vary between babies; symptom onset ranges from three to seventy-two hours.  Duration 
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for opioid withdrawal symptoms can last from 10-30 days; duration is dependent on the type of 
drug, dosage, and frequency the infant is exposed to in utero.   
Symptoms are managed medically with medications including morphine, methadone, and 
Buprenorphine.  To determine if the infant requires pharmacological intervention, healthcare 
providers use scoring tools such as Lipsitz, the Finnegan Neonatal Scoring Tool (FNAST), and 
the newest option, Eat, Sleep, and Console.  The FNAST tool quantifies the most common 
symptoms presented by the infant.  The FNAST contains 21 clinically significant items in three 
categories; each FNAST category is weighted differently in the total score.  The categories 
include central nervous system disturbances, metabolic, vasomotor, and respiratory disturbances, 
and gastrointestinal disturbances.  The pharmacologic treatment starts following three scores at 
or above eight or two scores at or above 12 on consecutive assessments.  Once symptom control 
has been achieved (as indicated by the FNAST scores), the weaning process starts.   
External Evidence 
Between 2009 and 2012, the incidence of NAS increased nationally from 3.4 to 5.8 per 
1,000 hospital births, totaling 21,732 infants with the diagnosis in the U.S with $316 billion 
spent annually.  The incidence rate for Texas increased by 60%, reaching 2.6 per 1000 births 
leading to $29 million in costs (Texas Department of State Health Services, 2017).  While not the 
highest national statistic, it is a rapidly growing concern across the state (Patrick, Davis, Lehman, 
& Cooper, 2015).  Bexar, Dallas, Harris, Tarrant, and Nueces counties had the highest number of 
NAS cases in 2015 (Texas Department of State Health Services, 2017).  Dallas County saw two 
in every 1000 births results in the development of NAS and spent millions annually on 
hospitalization of this patient population.  In 2006, 55% of Neonatal Intensive Care Units 
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(NICU) indicated having a written plan for NAS treatment (Patrick et al., 2016).  The American 
Academy of Pediatrics (AAP) published a clinical report recommending, “…each nursery should 
develop and adhere to a standardized policy for the evaluation and comprehensive treatment of 
infants at risk for or showing signs of withdrawal” (Hudak & Tan, 2012, pp. e554).  Patrick et al. 
(2016) indicated standardization of patient care and hospital policies would improve overall 
patient outcomes.  Despite this revelation, there is no nationally established standardized 
treatment guideline available to date for the care of this patient population.  
Internal Evidence 
Much like the growing national and state incidence rates, in 2017, Texas Health 
Presbyterian Hospital of Dallas (THD) experienced a 55% increase in infants with NAS.  
Currently, NAS patient treatment at THD includes symptom management via morphine.  A 
morphine protocol has been in place since 2014, yet not consistently prescribed or followed by 
all physicians.  The lack of a standardized adherence to the current protocol has led to morphine 
dosage weaning and escalation fluctuations, thereby increasing the length of time for the infant's 
treatment. Additionally, the FNAST tool is inconsistently used due to isolated staff training and 
an overall lack of knowledge pertaining to the 21 clinical definitions, leading to a great deal of 
subjectivity.  Staff ensure babies with NAS receive minimal stimulation (decreased lighting and 
noise and clustered care), which results in a reduction in parental participation.  Like other 
NICU’s across the county, THD does not have a comprehensive guideline for the treatment of 
patients with NAS.  
Development of the Clinical Question and Problem 
Considering the increase in the NAS patient population, lack of a comprehensive 
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guideline, extended length of stay and treatment, increased costs, and recommendations from 
professional associations, a comprehensive NAS treatment guideline is warranted.  A guideline 
inclusive of nonpharmacologic interventions and pharmacological treatment, used consistently, 
could improve patient outcomes.  Therefore, the question arises, in neonates with Neonatal 
Abstinence Syndrome (P), how does adding non-pharmacologic therapies to the current 
medication protocol (I) compared to current medication protocol alone (C) affect the length of 
stay (O) and duration of treatment (O) within one quarter (T)? 
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Chapter 2: Systematic Search, Evidence Synthesis & Project Models (EBP Process Steps 1, 
2, 3, & 4) 
Systematic Search 
A systematic search of three online databases was completed using the PICOT question 
as a guide, including, Cumulative Index of Nursing and Allied Health Literature (CINAHL), 
Cochrane Library, and PubMed.  Keywords or subject headings searched included, neonatal 
abstinence syndrome, length of stay, length of treatment, alternative therapies, non-
pharmacological treatment, pharmacological treatment, and medication management.  Since 
many versions of the terms pharmacological and therapies exist, the truncated search terms 
pharm* treatment, non-pharm* treatment, and alternative therap* also were used across all 
databases.   
The initial yield from CINAHL was 149, 266 potential articles.  Terms were combined 
using Boolean operators to narrow the yield to 13,760 articles.  The inclusion criteria of English 
language, full text, all infant sample, academic journals, and peer-reviewed were then added and 
resulted in a reduced total yield of 123 relevant articles.  Evaluation for relevancy resulted in a 
final total of 33 relevant articles (Appendix A, Figure A1).   
The Cochrane Library database was searched using key terms as listed above (and 
truncation symbol asterisk).  The search resulted in a yield of 335,763.  Combining key terms 
with the Boolean operator AND (to combine like terms) and OR (to consolidate like terms) 
resulted in a yield of 44,200 The inclusion criteria included review only, to isolate systematic 
review articles, while studies were included for non-relevance and duplicate reviews. The final 
yield was zero (Appendix A, Figure A1), indicating there were no Cochrane systematic reviews.   
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The final database searched was PubMed using the same key terms as mentioned above.  
The initial yield was 4,635,907.  Pairing the keywords with Boolean operators OR and AND 
resulted in a yield of 407,628.  Further narrowing the results, the inclusion criteria of full text; 
humans; English language; Newborn: birth-1 month was applied to bring the final yield to 97 
(Appendix A, Figure A1).   
A final hand search was performed of the 97 retained articles, yielding an additional 16 
articles, for a final yield of 113 potential articles to put forward for critical appraisal.  After 
review of title and abstract, a total of 8 articles were retained for the critical appraisal.  
Critical Appraisal 
Melnyk, Fineout-Overholt, Stillwell, and Williamson (2010) indicated, “Step 3: Critically 
appraise the evidence” follows the systematic search.  When comparing the research against the 
hierarchy of evidence as indicated by Melnyk, Fineout-Overholt, Stillwell, and Williamson 
(2010), the eight articles were 2-Level I, 5-Level IV, and 1-Level V.   
Rapid Critical Appraisal  
Eight articles were evaluated utilizing a rapid critical appraisal (RCA), which is the 
process of systematically assessing the quality, outcomes, and applicability of the evidence.  For 
identifying keeper studies, specific study design rapid critical checklists (RCAC) helped evaluate 
the literature.  For example, an RCAC of descriptive studies is different from the RCAC for 
qualitative evidence.  Additionally, a General Appraisal Overview (GAO) enabled a proper 
assessment of each study’s purpose, subjects, sampling techniques, and major variables, among 
other aspects of the studies.  The result of rapid critical appraisal with GAO & RCA yielded six 
keeper studies (Appendix B, Table B1).   
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Evaluation   
For ease of comparison study data, an evaluation table was developed (Appendix B, 
Table B2).  Aspects of the study were compared for differences and commonalities.  Across 
studies, independent variables included one or more of the following: breastfeeding, rooming-in, 
specialized bed, positioning, and non-insertion acupuncture.  Dependent variables included 
hospital length of stay and length of medication treatment, but not all variables were evaluated 
for their impact on the dependent variables (Appendix B, Table B3).  Two studies were 
systematic reviews (Bagley et al., 2014; Edwards et al., 2016), three were retrospective cohort 
studies based in a single facility (McKnight et al., 2014; Short et al., 2016; Well-Strand et al., 
2013), and the final article was a meta synthesis (Boucher, 2017).   
Studies in Bagley et al. (2014) and Edwards et al. (2014) reviews supported that BF had 
an impact on LOS and LOT (Appendix B, Tables B4 & B5).  Edwards and Brown (2016) found 
that breastfed infants increased symptom management, reduced need for medication treatment, 
delayed onset of symptoms, and a reduced length of treatment.  Additionally, breastfed infants 
had a shorter period of stay requiring only 12.5 days compared to 18.5 days, a profound 
difference from the current LOS within the SCN and justification for considering breastfeeding 
as supportive therapy.  The supportive nature of breastfeeding is further corroborated by Short, 
Gannon, and Abatemarco (2016) who conducted a retrospective cohort study appraising 
breastfeeding and its impact on the length of stay.  The median length of stay for non-
breastfeeding infants was twelve days, two days longer than breastfed infants.  Breastfeeding and 
length of stay have an inverse relationship, supporting previous results from other studies.   
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Like Bagley, Wachman, Holland, and Brogly (2014), findings by Edwards and Brown 
(2016) indicate infants who roomed-in had less severe symptoms of NAS, required less 
pharmacologic treatment, and a shorter length of stay.  Rooming-in enabled the mother and 
infant to be together, improving bonding, and decreased the admissions to the NICU; fewer 
admissions to the NICU ultimately reduces the hospital’s financial burden.  Furthermore, 
rooming-in was shown to aid in the reduction of length of stay and duration of treatment and was 
also statistically significant, according to Hunseler (2013) and Abrahams (2007).  Boucher 
(2017) reviewed the literature to evaluate rooming-in as a nonpharmacological therapy in the 
treatment of NAS symptoms and the impact on the length of stay.  The research examined led the 
author to believe that rooming-in may lead to a reduction in the length of the hospital.  The 
duration of treatment dropped by five days in the infants who roomed in with their mother.  The 
researchers suggest the developmental benefits of rooming-in outweigh the risks.     
Bagley, Wachman, Holland, and Brogly (2014) suggest a potential supportive and synergistic 
relationship between rooming-in and breastfeeding, who also evaluated the impact of rooming-in 
on NAS management.  This relationship is supported by McKnight, Coo, Davies, Holmes, 
Newman, Newton, and Dow (2015), who analyzed rooming-in and its impact on NAS symptom 
management.  Results indicate infants who roomed in required fewer days of pharmacologic 
treatment and reduced hospitalization.  While there was a higher proportion of breastfeeding 
infants in the rooming-in group, it was not a significant difference.  Rooming-in supported 
symptom management, independent of breastfeeding.  Rooming-in and breastfeeding may 
significantly improve outcomes if used in conjunction.  Edwards and Brown (2016) rooming-in 
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exploration included many infants who breastfed, combining two non-pharmacological 
interventions.   
Bagley, Wachman, Holland, and Brogly (2014) evaluated the use of a specialized bed in 
the management of NAS symptoms.  Using a rocking bed (with replicated intrauterine sounds) 
did not show a significant difference in withdrawal scores and led to sleep disturbance issues due 
to the constant noise; continuous noise can overstimulate an infant with NAS.  Non-oscillating 
water beds used with this patient population led to less medication for treating symptoms, 
although more research is required.  Specialized beds lack a determination to reduce the length of 
hospital stay.  Edwards and Brown (2016) found the use of waterbeds with breastfeeding infants 
supported less severe NAS symptoms and were less likely to require treatment with opiates 
resulting in a reduced LOT.  In comparison, a study examining the use of rocking beds found this 
intervention to be too stimulating to this patient population and therefore not a recommended 
treatment.   
Bagley, Wachman, Holland, and Brogly (2014) found in conjunction with the beds, 
placing the patient in a prone position positively supported symptom management.  While the 
results are positive for the use of positioning as an intervention, more studies are required to 
support the ongoing use and addition of this tactic.  Edwards and Brown (2016) suggest the use 
of positioning in the NAS population is a new concept, but one which requires consideration.  
Prone positioning appears to alleviate NAS symptoms and the infants placed in the prone 
position experienced lower withdrawal scores.  
Boucher (2017) reviewed the literature to evaluate acupuncture, noted as non-insertive 
acupuncture (NIA), as a potential treatment for NAS symptoms as well as NIA’s impact on 
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length of stay.  The authors suggest infants had better feeding sessions and their caloric intake 
was improved following NIA.  Sleep in this patient population was also improved just after NIA 
treatment was performed.  Agitated or infants who were hard to console appeared to have the 
most improved outcomes with the use of NIA treatment.  Edwards and Brown (2016) found 
acupuncture to be a supportive therapy for infants with NAS.  Infants appeared to have improved 
sleep and feeding following treatment with NIA, but the researchers did not link NIA with LOS 
or LOT.  Acupuncture is a controversial area and one that requires more research to support its 
acceptance.   
Synthesis 
From the evaluation table, interventions were extrapolated from each article and 
compared for their impact on LOS and LOT (Appendix B, Table B3).  Synthesis of the body of 
evidence revealed that the inclusion of breastfeeding, as a non-pharmacologic intervention, 
resulted in a statistically significant reduction in length of treatment and length of stay for NAS 
patients; specifically, hospitalizations were 3-19 days shorter in infants who breastfed.  From the 
10 studies reviewed by Bagley et al. (2014); Edwards et al. (2016) six supported that BF reduced 
infant LOS and LOT (Appendix B, Tables B4 & B5). 
Rooming-in was shown to enable the mother and infant to be together, improve bonding, 
and decrease the admissions to the NICU.  Rooming-in was shown to aid in reducing the length 
of hospitalization and medication treatment.  There were not enough studies to support that 
specialized beds, prone positioning or acupuncture had a reliable impact on length of hospital 
stay or symptom management.    
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Recommendations 
Based on the evidence, non-pharmacological interventions of breastfeeding and rooming-
in should be routine care for infants suffering with NAS symptoms.  These non-pharmacological 
interventions should be included into the care of the baby through the initial phase of withdrawal.  
When the infant’s symptoms can no longer be managed with non-pharmacological interventions 
alone, the Morphine protocol should then be added.  Given this contrasts with current practice, 
the recommendation for implementing these interventions is to develop and implement a 
comprehensive treatment guideline for the care of infants with NAS indicating initial treatment 
with non-pharmacological interventions of breastfeeding and rooming in and followed by the 
established morphine protocol.  
Evidence-Based Practice Model  
 To simplify the process of implementing a new evidence-based practice into the hospital 
setting, the Johns Hopkins Nursing Evidence-Based Practice Model (JHMEBP) (Appendix C, 
Figure C2) was adopted into this project.  The “PET” process includes the development of a 
practice or clinical question, the systematic search of the evidence, and then translation of the 
evidence into practice (Brooks-Staub, 2005).  According to the Daemen Library (2018), the goal 
of the model is to “ensure that the latest research findings and best practices are quickly and 
appropriately incorporated into patient care” (pp. 1).   Once the clinical question was established, 
a standardized search strategy was developed and used to search the most current and applicable 
evidence.  The evidence is thoroughly evaluated and synthesized to answer the clinical question 
for intervention development.  Once the intervention is developed, the project plan is initiated, 
and a change model is selected to begin the process of translating the science into practice.   
  13 
Lewin’s Change Theory  
Change is an inevitable part of healthcare.  To facilitate change related to this project, 
Kurt Lewin’s Change Model (Appendix C, Figure C3) will set the foundation for careful 
consideration of how this project would lead to practice change.  Lewin’s Change Model outlines 
three steps to change including unfreezing, changing, and refreezing.  During “unfreezing”, it is 
important to find ways to help others let go of old habits.  This can be done by increasing driving 
forces away from current patterns, decreasing the restraining forces causing negative movement 
from neutral, or a combination of the two (Nursing Theory, 2016).  Movement during the 
“change” stage includes process changes in thoughts, feelings, behaviors, or a change in all three 
that leads to a new sense of liberation.  “Refreezing” is when the change is now the new status 
quo.  Using this model, change would be planned, systematic, and thoughtful resulting in 
outcome success. 
In the first stage, staff and physicians would be made aware of the need for change 
through case studies, internal data, and current evidentiary recommendations (unfreezing).  
During this time, a new comprehensive and evidence-based guideline would be developed in 
partnership with staff and physicians who volunteers to participate in the project. Moving into 
the change stage, those impacted by the new guideline would receive education and training on 
the use of the guideline prior to implementation.  Practice expectations would be established and 
then the guideline would be implemented.  The refreezing stage would include data collection, 
celebration of successes, and review of outliers.   
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Chapter 3: Project Design and Methodology (EBP Process Steps 3-4) 
Project Design & Methodology 
To bring the evidence-based recommendation to fruition required planning included the 
development of a logic model, a timeline, and a Gantt chart all grounded in the evidence-based 
practice model and the change model previously mentioned.  Before the EBP project was 
launched, to ensure the full support of the project, an executive summary (Appendix D) was 
submitted to the interim Chief Nursing Officer (CNO) who then provided approval for 
implementing the project within the facility (Appendix E, Form E1).  Furthermore, two industry 
mentors signed on in support (Appendix E, Form E2 & E3).  Lastly, due to organizational 
requirements, I worked with the entity nurse scientist in preparation of Institutional Review 
Board (IRB) approval.  A Quality Improvement Evidence-Based Practice Assessment form was 
completed and submitted to the IRB for project determination (Appendix F, Ethics Review Form 
F1 & F2), and IRB support was secured (Appendix F, Ethics Review Form F3). 
Operationalization Plan 
During the beginning of this project, it was important for every unit to have input, 
therefore an interdisciplinary team was created, called the NAS Council.  This council was 
comprised of one individual from each of the women and infant units who would interact or 
provide care for the target patient populations (women with substance use issues and their 
newborn baby).  From this team, the logic model, timeline, and Gantt chart were completed 
including the required milestones, tasks to achieve each milestone, responsible parties, and all 
deadlines associated.  
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Timeline and Gantt chart 
A timeline was created using the goals established from the logic model (Appendix G, 
Table G1).  Milestones were fixed as checkpoints on the timeline.  In evaluating the milestone, 
tasks were laid out for each checkpoint.  The timeline enabled the project to stay on track with 
forward momentum.  To further visualize the timeline and associated milestones/tasks, a Gantt 
chart was developed (Appendix G, Figure G2).  A Gantt chart is a visual tool and schedule 
representing the milestones of the project with assigned dates.  Under those milestones, the 
individual associated tasks were highlighted, each with a date of completion assigned. 
Logic model  
A Logic Model was created to define the inputs (resources, contributions, and people), 
outputs (activities, services, and events), and outcomes (results or changes related to the projects 
interventions) (Appendix G, Figure G1).  The logic model helped to create an overview of this 
project by identifying the short- and long-term goals, including that the NAS guideline was 
finalized and approved by medical director, and the expected outcomes of reduced length of 
hospital stay and length of medication treatment.  From these goals, we evaluated “inputs”, 
which are the things that will be invested in this project such as finances, staffing, technology, 
and equipment.  Additionally, we investigated the outputs to identify the activities currently 
being practiced and pertaining to the project as well as the people those activities are aimed.  The 
logic model helped to isolate the information known about the project and identify 
uncontrollable external factors may impact the project. Through this model, we were able to 
pinpoint what is readily available and what is missing so the gaps can be filled.  As the project 
developed, the logic model was adjusted to include new information and details. 
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Project Progress 
Following several initial meetings with the NAS Council, the first and most important 
task identified by the council members was to draft, edit, and finalize a comprehensive treatment 
guideline that includes the current morphine protocol and the evidence-based non-
pharmacological interventions as outlined in the body of evidence.  The team met with the 
medical director and began the first draft of the guideline.  The guideline was shared with one of 
the industry mentors for additional input as he was the content expert.  This process took 
approximately 6 months to complete.  The final draft of the NAS guideline was submitted 
through the policy committee for approval and upload to the internal policy database (Appendix 
H).   
Through the many meetings regarding the guideline, the NAS council representatives 
expressed concerns of staff and physician’s lack of baseline knowledge as evidenced by the lack 
of consistency in following the weaning and escalation steps outlined in the current morphine 
protocol.  An additional moment of concerned sparked from an obstetric department meeting in 
which opiates during pregnancy was a topic of discussion.  During the meeting, NAS was 
mentioned.  One physician asked, “What is NAS?”   This situation was discussed during an NAS 
Council meeting.  The Council recommended developing an education module to prepare staff 
and physicians for the implementation of the guideline.  Further discussion led to an additional 
recommendation of developing and adding education on the topics of addiction, trauma-informed 
care, NAS interventions, Finnegan scoring, in addition to the new treatment guideline.  This 
would establish a solid foundation to elevate the staff and physician’s knowledge and 
understanding of these topics.  The timeline and Gantt chart was updated with the new milestone 
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and tasks including the following: the council developed sub-committees and each group would 
take a topic and develop an evidence-based module for consideration.  The NAS Council met an 
additional four times to edit and finalize the modules of which they submitted to the following 
for approval: 
 Neonatology Department – medical director and content expert 
 Pediatric Department – medical director and one additional physician representative  
 Women and Infant’s Leadership Team – managers of impacted departments and 
director  
 Education Department –women’s and infant’s educators   
EBP Model 
 From my experience with Gracelynn, I use the Johns Hopkins Nursing Process Model for 
evidence-based implementation to guide this project from start to finish.  I first formulated a 
background question.  I used the question to extract key terms to search online the online 
databases of CINAHL, PubMed, and Cochrane library for the most current and applicable 
evidence.  I synthesized the evidence to answer the clinical question and then translate the 
evidence into practice.    
Change Model 
 To facilitate a planned change, I used Lewin’s Change Theory, to break down the project 
into three stages including “unfreezing” old habits, implementing the “change” we want to see, 
and “refreezing” the new habit as the best practice.  In the “unfreeze” phase, we educated all 
stakeholders through case studies and an education package.  When the “change” was planned 
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for rollout, we implemented the guideline, monitored for compliance, redirected those who fell 
out of compliance back to the guideline and reminded them of why we were making this change.  
As we entered the “refreeze” phase, we collected data and reported out our project in several 
different settings.  We celebrated our successes and planned growth and development of the 
project.  
Final budget 
The estimated data from the logic model enabled me to draft an email, to the director and 
interim CNO, that would highlight the financial impact of the project would make on the 
organization.  Initial estimates included costs associated with items such as projectors and 
computers and since the unit already owns these items, they become budget neutral.  The final 
budget consisted of time spent for staff and physicians to complete the education ($4000) prior to 
the implementation of the guideline as well as the time spent by the project’s members to 
develop the education modules and the guideline ($5500).  With the understanding the only 
financial requirement would come in the form of time spent reviewing the education modules, 
the director, and interim CNO gave the greenlight to move forward with the project’s 
implementation. 
Data Collection Plan 
The following were deemed as process indicators and outcome measures to be collected 
in relation to this project: 
Process indicators 
• Percent of providers education/completed modules 
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• Pre and post-test reliability scores 
Outcome measures 
• Length of hospital stay 
• Number of days of pharmaceutical treatment outcome 
• Pre and post intervention total hospital cost by NAS diagnosis by year 
Pre - Post knowledge transfer assessment surveys evaluate the effectiveness of staff and 
physician’s education about providing care to infants with NAS.  It was also important to track 
the number of staff and physicians who completed the education modules to ensure the message 
reached as close to 100% of the target audience as possible.  These data points would be 
collected direct from the SharePoint platform in which the education modules were housed and 
by the assigned project members only.  No identifying information was collected from the staff 
or physicians other than job role.   
Outcome measures would determine the efficacy of the intervention and included the 
length of hospital stay, length of morphine treatment and will demonstrate the project’s success 
or failure. The outcomes data collection plan consisted of two parts:  (1) Pre project and post 
project data obtained by submitting a request to finance for a list of infants (account number, 
medical record number, date of birth, date of discharge, ICD9/10 diagnosis code, total cost of 
hospital stay) with a diagnosis related to drug withdraw and their total LOS, and (2) Pre project 
and post project data obtained by submitting a report request to pharmacy (including the above 
report) detailing the patients from the list who were treated with morphine (date morphine 
initiated, date morphine discontinued, and the total duration of morphine treatment).  Data 
stewardship was implemented to ensure all private patient information was kept secure, 
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including all data collected were deidentified, assessed and aggregated prior to dissemination.  
Ownership of the data remained secure on a password locked spreadsheet with limited access to 
those involved in the data collection process.  Access of data was limited to NAS council 
members in charge of data collection. 
Data Analysis Plan 
The final dataset was evaluated for any missing data and cases were removed with any 
missing data points.  Absolute differences for knowledge transfer scores, LOS, LOT were 
calculated by case for the various time periods within the project.  Mean differences were 
reported for by case outcomes to demonstrate success or failure of the education or intervention 
in this setting.  Absolute differences for number of providers educated and total costs by 
diagnosis were calculated for the various time periods within the project.   
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Chapter 4: Project Implementation, Outcomes, Impact, and Results (EBP Process Steps 4 
& 5) 
Process Indicators/Milestones 
The first milestone included developing, reviewing, finalizing, and submitting the 
evidence-based treatment guideline through the policy committee (Appendix H).  Once this 
process was complete, the guideline was uploaded into the hospital system’s online policy 
database.  The second milestone was the completion and launching of the evidence-based 
education modules including the accompanying pre and posttests.  The education module would 
be open to participants for 6 weeks.  Unit leaders were asked to add information about 
participation to daily huddles, weekly emails, and individual communications, which kept the 
project fresh on the participant’s minds.  Once the 6 week period was complete, data was 
collected from the SharePoint platform, requested from finance, and requested from pharmacy.   
Lessons Learned    
One of the most important lessons learned was the process for requesting a specific 
platform that would meet the needs of the project.  In the implementing hospital system, there are 
limited number of available platforms.  During this project, I learned there is an established 
method of requesting platforms.  The project lead is required to submit a request to a centralized 
network of hospital system educators.  That request is then taken to the education council to 
review and investigate options.  If a platform is available, the council will notify the requestor 
and obtain the appropriate access for use.   
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Barriers  
One barrier to achieving outcomes for the project was the platform used to house the 
education intervention modules.  The SharePoint platform enabled the staff and physicians to 
complete a pre-test (three questions), review the education material, and a post-test (same three 
questions).  Several staff reported an inability to log onto the SharePoint.  Additionally, 
navigation of the education material was not ideal for staff, who had to use the back button to 
take them to the home page to continue to the next phase of the education package versus a 
smooth logical transition to the next module.  SharePoint was chosen because of its ability to 
provide the pre/post-testing of staff completing the educational modules.  Furthermore, since 
physicians are not internal employees of the organization with a hospital email address, they 
could not be added as users on the SharePoint site, which hindered the educational intervention 
delivery   
Because of the platform challenges, 52% of available staff and physicians were not able 
to log on and successfully complete the education package.  Additionally, only one physician 
completed all the modules, with one other partially completing.  Due to the lack of physician 
participation, inconsistency in practice is still an issue in need of resolution.   
Solutions  
As we ended this project, I met with leaders within the entity and discussed the desire to 
relaunch the education module in order to reach the participants we missed during our first run.  
It was decided a new platform would be necessary.  I worked with the education department to 
find a platform that will meet the needs of the project so that physicians can participate in the 
education and evaluation.  The aim was to have 100% completion by all audience members by 
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December 2020.  A request was submitted, and the education council reviewed the request 
several times.  Unfortunately, there is not a platform that will be easy for staff and physicians to 
access that will allow us to collect pre and post knowledge transfer assessments.  This put the 
NAS council in a position where we had to decide to either reuse the SharePoint site or go out of 
the system and find a platform unsupported by the hospital system.  To date, this is still being 
investigated by the education council members in hopes of finding a platform to meet our needs.   
Project Results 
As mentioned previously, the following were process indicators for this project:  percent 
of provider’s education/completed modules and pre and post-test reliability scores.  The module 
was launched and given a six-week deadline.  Following the deployment of the education 
module, of the 120 available staff and physicians who were able to access the platform where the 
modules were housed, 48% were able to complete the entire education package (Appendix I, 
Table I6).  Pretest results included the following: trauma-informed care (94%), addiction (90%), 
Finnegan Scoring (57%), NAS interventions (72%), and the new NAS treatment guideline 
(93%).  For each of the five education components, participating staff and physicians achieved a 
100% score on the posttest after reviewing the education presentation, which indicates the 
education provided was successful (Appendix I, Figure I3).   
Once the education module deadline was met, the NAS guideline was officially 
implemented into practice.  Outcome measures collected included the length of hospital stay, 
length of pharmaceutical treatment (morphine), and total hospital costs NAS diagnosis code and 
by year.  Data was collected for years 2014, 2015, and 2016 to establish baseline data.  In 2017, 
there were 23 cases of NAS who stayed an average 31 in the hospital and received an average of 
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34 days of morphine treatment.  In 2019, there were 19 cases of NAS who stayed an average of 
17 days and received an average of 20 days of morphine treatment (Appendix I, Figure I4).  
These results indicate the implementation of an evidence-based treatment guideline paired with a 
comprehensive education package were successful in reducing the length of stay by 14 days and 
the length of morphine treatment by 14 days.  This resulted in a savings of $307,136 in hospital 
costs (Appendix I, Figure I5).     
Data Collection 
Outcome measures collected from a requested finance report included the number of 
NAS cases, length of hospital stay, and the total cost of hospitalization by diagnosis and year.  
Baseline data was collected for the years of 2014 through 2017 and post-intervention data was 
collected for years 2018, and 2019.  The finance report also included individual patient medical 
record number of which a pharmacy representative could use to extrapolate the start and end date 
of morphine treatment.  Raw data was collected from the SharePoint site including total number 
of staff completing the entire education module, total number of staff partially completing the 
education module, pretest scores by job role for each education section, and posttest scores by 
job role for each education section.   
Data Analysis 
Using the finance report, the number of NAS cases were totaled and reported by year.  
The total length of stay was collected from each NAS case and then averaged and reported by 
year.  Associated hospital costs for each NAS case were totaled and reported by year.  The 
finance report was submitted to the NAS council pharmacy representative.  She used the account 
numbers to conduct a manual extraction of data including the date of morphine initiation and the 
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date of morphine discontinuation.  From this, each case had a total length of stay.  The average 
length of hospital stay was calculated and reported by year.    
Outcome Measures 
 Of the 120 available staff and physicians who were noted as potential participants, 118 
completed at least one of the 16 components of the education module.  Fifty-eight completed the 
entire module, which translates to 48% of staff completed 100% of the module.  We looked at 
the pre-test scores and knew the Finnegan scoring module would be tough as the scoring tool has 
a great deal of subjectivity.  The goal was to reduce the subjectivity with the education module 
by providing clear definitions of each of the 21 components of the scoring tool.  Following the 
completion of the education modules, each of the 58 participants achieved 100%, which means 
the education module was effective.   
To evaluate our outcome measures, finance pull ICD9 and ICD10 diagnosis codes 
associated with NAS and the patient’s LOS.  In 2017, there were 23 cases of babies with NAS 
who stayed an average of 31 days and were treated for an average of 34 days.  After the 
implementation of the guideline and the completion of the education modules, the same finance 
reports were pulled.  In 2019, there were 19 cases who stayed and average of 17 days and were 
treated for an average of 20 days.  Overall, while the number of NAS cases remains steady, the 
interventions had an important impact on the average length of stay and the length of treatment.   
Outcome Analysis 
While the number of NAS cases remained steady, differences in absolute numbers for 
LOS, LOT, and the cost of hospitalization showed a downward trend (Appendix I, Figure I4), 
which was an expected finding based on the synthesized body evidence.  
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Financial Impact 
The organization began considering the NAS patient population in 2014 due to its 
exorbitant cost of care. Project implementation occurred in late 2018.  Impact outcomes were 
evaluated pre-project implementation in 2017, when the hospital had 23 patients with NAS who 
stayed an average of 34 days, accumulating a total of $499,709 in hospital charges.  In 2018, 
during project implementation, there were 28 cases who stayed 13 fewer days than the year 
before, resulting in a total cost of $313,799.  In 2019, post project implementation, there were 19 
cases of NAS who stayed an average of 17 days at a cost of $192,573.  The total savings from 
2017 to 2019 was $307,136, which supported the findings in the body of evidence (Appendix I, 
Figure I5).     
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Chapter 5: Project Sustainability Discussion, Conclusions, and Recommendations (EBP 
Process Step 5 & 6) 
Implications of Project Results 
By providing foundational education and implementing a standardized treatment 
guideline for the care of infants with NAS, the healthcare team practices consistently resulting in 
a reduction in hospitalization and costs.  There has been a noted shift in culture within the units 
involved in this project.  I have seen staff identify external educational material still using old 
terminology such as “addicted” in relation to the babies impacted with NAS.  Babies are not 
“addicted” but rather harbor a physical dependence on the medication they were exposed to.   
This same shift in staff and physician perception has also been impacted the relationship 
between staff and the mothers of these patients.  Through the trauma-informed care education, 
the staff now understand the mother’s history and past trauma(s) may contribute to her use of 
drugs.  Additionally, staff and physicians now know addiction is a medical condition rather than 
a choice.  Shifting staff perceptions and attitudes towards the mother has led to staff empowering 
the mother to take an active and engaged role in her baby’s treatment.    
There has been a marked improvement in the relationship between staff, physicians, and 
Child Protective Services (CPS) following the implementation of this project’s interventions.  
The improved partnership with CPS enabled staff to advocate on behalf of the mother and baby 
and develop safety plans with CPS that not only meet case worker expectations but enabled on-
going incorporation of non-pharm interventions into patient’s care by the mother.  
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Project Sustainability Plans 
Two quarterly reports will be generated: 1) a quarterly report for the number of NAS 
cases, the total length of hospital stay, and associated hospital costs will be requested by 
appointed NAS Council member(s) and submitted to a finance representative.  2) The finance 
report will be shared with the NAS Council pharmacy representative in which they will collect 
the total duration of morphine treatment on each NAS case identified in the finance report.  To 
facilitate this, I added quarterly report appointments to the calendar of each of the NAS Council 
members involved in data management.  Assigned data collectors will keep a secure spreadsheet 
of all data for ongoing monitoring for trends.  Discussion of quarterly data will occur at specified 
NAS Council meetings and action plans developed to address negative trends.  To ensure the 
NAS treatment guideline is based on the latest evidence, the guideline will enter the 2-year 
policy review cycle, in which the evidence will be explored for any new recommendations to 
update the guideline.  Quarterly reports and updates to the guideline will be communicated via 
daily huddles, email, and weekly newsletters.   
Implications of Results to the Community/Organization 
 While Gracelynn was not able to benefit from this project, other babies like her will 
benefit from the consistent evidence-based care at a significantly reduced cost.  Dissemination of 
this project via poster fairs (Appendix J, Figure J1), podium presentations, and publication will 
benefit other healthcare facilities seeking to improve the care they deliver their own patients with 
NAS.  Through our improved partnership with CPS case workers, we expect CPS caseworkers 
will share their experiences with other organizations, highlighting our work as the benchmark for 
successful outcomes with the NAS population.  One of the most powerful implications of this 
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project is the mothers will feel a sense of connection and ownership because we have 
incorporated them into the treatment team and educated them on the vital role they play in their 
baby’s treatment journey.     
Key Lessons Learned 
The first key lesson learned through this process is that evidence-based practice is 
effective in addressing clinical issues.  In this case, as the evidence suggests, the implementation 
of a comprehensive treatment guideline for the care of infants with NAS reduced the length of 
hospital stay, the duration of morphine/medication treatment, and can save the hospital thousands 
of dollars for our organization.  Second key lesson is that consistent utilization of the guideline is 
key to ongoing success.  Toward that end, the sustainability plan will ensure data points are 
regularly evaluated and negative trends are investigated using quality improvement process, such 
as root cause analysis.  
The third key lesson learned is that barriers to success must be anticipated and plans 
developed to address those barriers.  When faced with unplanned obstacles, it is important to 
evaluate all options and make the best decision based on those available options.   The options 
may not include the perfect solution, but project leaders should move forward, learn from the 
situation, and adjust later as the project fully develops.  The final key lesson for this project was 
the despite best laid plans, unforeseen flaws in the plan are bound to happen, such as the 
inadequacies of the educational module platform and inaccessibility to physicians.  Key lessons 
learned in this project will facilitate better project process and outcome success with the next 
one. 
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Project Recommendations 
The best evidence-based treatment for patients with NAS is consistency in guideline 
implementation, which guarantees a standard of care across patients, providers, and time.  When 
this project began, adherence to the new guideline was varied.  Continuing to offer the NAS 
educational modules will be of utmost importance – in orientation of new nurses as well as 
annual competency blitz.  This will ensure that babies are treated appropriately and are 
discharged in the appropriate time period.   
With the success with NAS patients in our organization, there is the potential for 
implementing the new NAS guideline system-wide.  One challenge to system-wide 
implementation is that two different neonatology groups care for these patients.  The practice 
approach varies between these two provider groups.  The key to system-wide implementation 
will be the project leader cultivating relationships with these provider groups, helping them 
understand the evidence underpinnings of the guideline, the success of this project and how 
appointed NAS Council member can help them implement the guideline in their organization, 
including ongoing updates to ensure its evidence-based foundations. 
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Chapter 6: DNP Practice-Scholar Role Actualization 
Role Impact  
I define my leadership style as a combination of transformational, situational, and servant 
leadership (Appendix K, Figure K1).  During this project, I drew on components of each of these 
leadership styles to motivate and stimulate those involved in the project’s development, 
implementation, and completion.  As a servant leader I ensured staff impacted by this project had 
a voice and encouraged their participation, which fostered their professional growth through a 
trusting give and take relationship.  When issues developed, I called upon my situational 
leadership skills and reassessed the situation with my team.  We examined participants and their 
readiness to receive change.  From this, I adjusted my methods to meet their needs and improve 
their commitment to the project.    
As a DNP clinical expert, my impact on the organization is broad and stretches from 
finance, through policy development, patient outcomes, and beyond.  I plan to draw on my DNP 
program experience to lead my organization to improved healthcare delivery through translation 
of the best and most current evidence into practice.  I hope to implement this guideline into 
practice system wide to each of our entities may delivery high-quality evidence-based care.  I 
have recently started hosting talks with visiting nursing students about my experience in the DNP 
program in hopes of inspiring them to continue their education and contribute to the ongoing 
success of the nursing profession.  
When evaluating my career trajectory, I plan to continue to increase my engagement 
within my organization by taking on additional leadership roles.  Should an opportunity to 
advance present itself, I am now more confident in my abilities to move to the next level.  I will 
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continue to push myself beyond my comfort level to foster growth both personally and 
professionally.  I believe this project has provided an opportunity for others (within the 
organization) to see my potential and therefore seek me out for important projects and tasks.  I’m 
open to any and all opportunities that come my way and I contribute that directly to my 
experience in this program.  
Summary   
Through a keen awareness of my individual strengths and emotional intelligence, as they 
have been woven through this program, I have found success.  With the regular use of self-
reflection, I have focused energy on improving my areas of opportunity, which will benefit my 
future career momentum.  This program has not only helped me improve as a leader and a DNP 
clinical expert but empowered me to seize each opportunity as a monumental event to explore 
things I would not normally have tried.    
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Appendix A. Systematic Search  
Figure A1 Systematic Search Strategy Flowchart 
 
1 = Bagley, et al., (2014); 2 = Edwards, et al., (2016); 3 = McKnight, et al., (2016); 4 = Short, et 
al., (2016); 5= Welle-Strand (2013); 6 = Boucher et al., (2017) 
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Appendix B. Critical Appraisal 
Table B1: Levels and Type of Evidence 
  
 1 2 3 4 5 6 
 
Level I: Systematic review or meta-analysis 
X X -- -- -- -- 
 
Level II: Randomized controlled trials 
-- -- -- -- -- -- 
 
Level III: Controlled trials without randomization 
-- -- -- -- -- -- 
 
Level IV: Case-control or cohort study 
-- -- X X X -- 
 
Level V: Systematic review of qualitative or descriptive studies 
-- -- -- -- -- X 
 
Level VI: Qualitative or descriptive study (includes evidence 
implementation projects) 
-- -- -- -- -- -- 
 
Level VII: Expert opinion or consensus 
-- -- -- -- -- -- 
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Lipsitz-Neonatal Withdrawal Inventory, LOS-Length of Stay, LOT-Length of Treatment, MA-Meta Analysis, MD-Mean Difference, MIR, Maternal Infant Relationship, Med Req-Medication Required, 
Mgt-Management, ML – Medline, Modified Finnegan-MOTHER NAS Scale, MSO4-Morphine, NAS-Neonatal Abstinence Syndrome, N/D – Not Determined,  NIA-Non-insertion Acupuncture, NNWI-
Neonatal Narcotic Withdrawal Index, Nonpharm-Nonpharmacologic treatment, NOS-Neonatal Opium Solution, NWI-Neonatal Withdrawal Inventory, OR-Odds Ratio, Pharm-Pharmacologic treatment, 
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RR-Risk Ration, RX-Treatment, SC-Supportive Care, SD-Standard Deviation, Sen/Spec-Sensitivity/Specificity, SX-Symptoms, SZ-Seizures, TO-Tincture of Opium, TX-Treatment, TY-Total Yield, 
WKS-Weeks, WMD-Weighted Mean Difference. 
 
Appendix B. Critical Appraisal & Synthesis 
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IV 1 - BF 
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IV 4 – Position 
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DV 1 - LOS 
DV 2 - LOT 
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-13/14 studies found 
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BF findings stat sig  
 
Conclusion 
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3. McKnight et al., (2015) 
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risk of Neonatal 
Abstinence Syndrome.  
American Journal of 
Perinatology, 33(05), 495-
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Examine RI 
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N/A Design: 
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and 2014 w/ 
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 Stat sig inverse 
relationship 
between BF and 
LOS (p=0.008) 
(Adjusted p=0.05) 
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Using ICD-9 has been 
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potential incorrect coding  
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Large sample size 
Stat sig results 
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N/A Design: 
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1 = Bagley, et al., (2014); 2 = Edwards, et al., (2016); 3 = McKnight, et al., (2016); 4 = Short, et al., (2016); 5= Welle-Strand 
(2013); 6 = Boucher et al., (2017) 
LOS – length of stay, LOT – length of treatment, n/m – not measured, ↓ - decreased, * - statistical significance, incon - 
inconclusive 
 
 
Appendix B. Critical Appraisal & Synthesis 
Table B3: Nonpharmacologic Interventions and Impact on LOS/LOT 
 Breastfeeding Rooming-in Beds Position Acupuncture 
Acupressure 
1 
LOS↓* LOS↓* 
LOT↓* 
LOS n/m 
LOT↓ 
LOS n/m 
LOT n/m 
LOS n/m 
LOT n/m 
2 
LOS↓ 
LOT↓ 
LOS↓ 
LOT↓ 
LOS↓ 
LOT n/m 
LOS n/m 
LOT n/m 
LOS n/m 
LOT n/m 
3 
-- LOS ↓ 
LOT n/m 
-- -- -- 
4 
LOS ↓ 
LOT n/m 
-- -- -- -- 
5 
LOS n/m 
LOT↓* 
-- -- -- -- 
6 
-- LOS↓* 
LOT n/m 
-- -- LOS incon 
LOT n/m 
Synthesis 
3 of 3 reduced 
LOS 
2 of 2 reduced 
LOT 
4 of 4 reduced 
LOS 
2 of 2 reduced 
LOT 
1 of 2 reduced 
LOS 
1 of 2 reduced 
LOT 
None evaluated 1 incon 
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LOS – length of stay, LOT – length of treatment, n/m – not measured, ↓ - decreased, * - 
statistical significance, RI – Rooming-in, BF - Breastfeeding 
 
 
Appendix B. Critical Appraisal & Synthesis 
Table B4: Systematic Review by Bagley et al. 
 LOS LOT 
Abdel-Latif (2006) BF = ↓* n/m 
Dryden (2009) n/m n/m 
McQueen (2011) n/m n/m 
Pritham (2012) BF = ↓ n/m 
O-Connor (2013) n/m n/m 
Wachman (2013) BF = ↓* n/m 
Welle-Strand (2013) n/m BF = ↓* 
Hunseler (2013) RI = ↓ RI = ↓ 
Abrahams (2007) RI = ↓* RI = ↓* 
D’Apolito (1999) n/m n/m 
Oro (1988) Bed = ↓ n/m 
Maichuk (1999) n/m n/m 
Filippelli (2012) n/m n/m 
Recommendation BF & RI reduce LOS RI reduce LOT 
 
LOS – length of stay, LOT – length of treatment, n/m – not measured, ↓ - decreased, * - 
statistical significance, RI – Rooming-in, BF - Breastfeeding 
 
Appendix B. Critical Appraisal & Synthesis 
Table B5:  Systematic Review of Non-Pharmacological Interventions by Edwards et al. 
 LOS LOT 
Addel-Latif et al. (2006) n/d  n/d  
Abrahams et al. (2007) RI↓* RI↓* 
Abrahams et al. (2010) RI↓* n/d 
Ballard (2002) BF↓ BF↓ 
D’Apolito (1999) n/d  n/d  
Filippelli et al. (2012) n/d  n/d  
Hodgson & Abrahams (2012) n/d  n/d  
Isemann et al. (2011) BF↓ BF↓ 
Maichuk et al (1999) n/d  n/d  
McQueen et al. (2011) n/d  n/d  
O’Connor et al. (2013) n/d  n/d  
Oro & Dixon (1988) n/d  n/d  
Schwartz et al (2011) n/d  n/d  
Welle-Strand et al. (2013) n/d BF↓ 
Recommendation BF & RI reduced LOS BF reduced LOT 
 Appendix C. EBP and Change Models 
 
Figure C1 Johns Hopkins Nursing Evidence-Based Practice Model (JHMEBP) 
 
 Appendix C. EBP and Change Models  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C2 Lewin's Change Model 
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Appendix D. Executive Summary 
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Appendix E. Letters of Support & Agreement 
Form E 1 Letter of Support CNO 
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Appendix E. Letters of Support & Agreement 
Form E 2 Industry Mentor Agreement – Chan 
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Appendix E. Letters of Support & Agreement 
Form E2: Industry Mentor Agreement – Chan Page 2 
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Appendix E. Letters of Support & Agreement 
Form E 3 Industry Mentor Agreement - Kakkilaya 
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Appendix F. Ethics Review   
Ethics Review Form F1 Faculty Attestation of Compliance with the UTT DNP EPIP Ethics Form 
I attest that I have reviewed the UTTYLER DNP EPIP ETHICS FORM that the DNP student has 
completed based on justification using the UTTYLER DNP PROGRAM IRB DISCERNMENT FORM. 
I agree that the need for ethics review determination is correct and this DNP EPIP requires: 
 
X FM Review Only 
 -HIPAA ethics review by DNP Ethics Board 
 HIPAA review form completed 
 Organizational IRB review (based on policies of the organization in which the EPIP will 
be implemented) 
 
_Ellen Fineout-Overholt__      _11-10-18_ 
Faculty Mentor Signature      Date
 57 
 
Appendix F. Ethics Review 
Ethics Review Form F 2 QIEBP Worksheet 
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Appendix F: Ethics Reviews 
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 Appendix F. Ethics Review 
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Appendix F. Ethics Review 
Ethics Review Form F 3 Texas Health Resources IRB Approval Letter 
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Appendix G. Implementation Plan 
Table G1: Logic Model 
Program Name: Adding Non-Pharmacological Interventions to a Morphine Protocol to Improve the Treatment of Infants 
with Neonatal Abstinence Syndrome: An Evidence-Based Innovation Project 
Program Goal: Improve the care and treatment of infants with NAS thereby reducing the treatment time and length of 
hospital stay 
 
Resources/Inputs: (What resources are needed for the project to be successful… The human, financial, organizational, and 
community resources available to do the work.)   
 Necessities List Associated Costs Wish List 
Human 
Resources 
 12 - Neonatologists 
 156 - Staff RN (FCC, SCN, 
NICU) 
 5 - Nurse leaders (FCC, SCN, 
NICU) 
 3 - OT/PT 
 15 - PCTs 
 10 - Administrators 
 10 - Senior leaders 
 12 NAS committee members for 
policy creation, review, and 
finalization 
 12 – Neonatologists: UTSW 
Salaried MDs 
 65 - Staff RN (FCC, SCN, 
NICU): 45/hr 
 5 - Nurse leaders (FCC, SCN, 
NICU): $60/hr 
 3 - OT/PT: $35/hr 
 15 – PCTs: $14/hr 
 10 – Administrators: $80/hr 
 10 - Senior leaders: $75/hr 
 12 NAS committee members: 
$45/hr 
 Support from all healthcare 
providers 
 Positive attitude and graceful 
adaptation from healthcare 
providers toward protocol 
changes  
 Support from senior leaders and 
administrators  
Office 
Supplies 
 Laptop 
 Projector 
  Budget Neutral 
 Budget Neutral 
 Already own these items 
Organization 
Resources 
 Access to patient 
charts/information 
 Access to NAS protocols, 
policies, and/or procedures 
 Staff breakroom for educational 
training 
 Access to pt. information: No 
charge 
 Access to NAS protocols, 
policies, and/or procedures: No 
charge 
 Staff breakroom: No charge 
 None 
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Resources/Inputs: (What resources are needed for the project to be successful… The human, financial, organizational, and 
community resources available to do the work.)   
 Necessities List Associated Costs Wish List 
 Food and drinks for each 
educational session 
 Breastmilk refrigerators 
 Breastmilk freezers 
 Breastmilk pumps 
 Disposable breast pump kits  
 Bottles 
 Nipples 
 Breast pump supply cleaning 
kits 
o Palmolive dish soap 
o Large pink basin 
o Bottle brush 
  
All items are budget neutral as they 
are included in the cost of 
admission: 
 Breastmilk refrigerators: $147 x 
34 
 Breastmilk freezers: $350 x 2 
 Breastmilk pumps: $150 x 34 
 Disposable breast pump kits: 
$25/each 
 Bottles: $0.10/each 
 Nipples: $0.06/each 
 Breast pump supply cleaning kit: 
$1.50/each 
 
OUTPUTS OUTCOMES 
Activities  
(What do project staff 
need to do?) 
Audience(s) 
(What population 
needs to be engaged?) 
Short-Term 
(At launch) 
Mid-Term  
(1-month) 
Long-Term 
(3-months) 
Review current NAS 
treatment protocol.  
Revise protocol based 
on conclusive 
evidentiary support 
from systematic 
search to include non-
pharm interventions: 
BF & RI 
Active stakeholders  Protocol will be 
finalized & approved 
by medical director 
then placed as active 
in Policy Connect for 
launch 
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OUTPUTS OUTCOMES 
Activities  
(What do project staff 
need to do?) 
Audience(s) 
(What population 
needs to be engaged?) 
Short-Term 
(At launch) 
Mid-Term  
(1-month) 
Long-Term 
(3-months) 
Educate passive 
stakeholders 
regarding updated 
NAS treatment 
protocol and 
implications to 
practice 
Passive stakeholders 
required include: 
Neo MDs, Staff RNs 
in SCN, NICU, & 
FCC, PS, & NS:  
100% passive 
stakeholders received 
education by launch 
date  
100% infants admitted 
with dx of NAS will 
receive treatments as 
outlined in new protocol  
Reduced LOS and 
LOT 
Chart reviews Cyndi & Catrina  100% of admitted 
infants with NAS will 
have chart reviews 
evaluating stakeholder 
compliance with new 
protocol 
100% staff compliance 
with updated protocol 
Ongoing data 
collection 
Cyndi & Catrina  100% of patients with 
NAS will have data 
extracted and retained 
for review following 
project completion.   
Preliminary data 
comparison of pre and 
post data will be 
conducted to determine 
efficacy of new protocol 
100% of patients with 
NAS will have data 
extracted and retained 
for review following 
project completion.   
Final data comparison 
will be completed and 
reviewed. 
 
External Influencing Factors 
Environment/Setting 55555  
Other Programs Parkland:  NAS Project Development and Mommies Program (Dr. Venkat Kakkilaya) 
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Influences Dr. Venkat Kakkilaya (NAS project MD champion); Dr. Christina Chan (Neonatal Medical Director 
at THD) 
 
Assumptions 
 Staff believe mothers who use drugs do not care about their babies and do not want to stay with their baby in the 
hospital 
 Staff believe that it doesn’t matter if the mother rooms in or not, the baby is best treated with pharmacological 
interventions 
 Staff believe all mothers with a history of drug use (but not currently using) should now be allowed to breastfeed 
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Appendix G. Implementation Plan 
 
Figure G1 Gantt Chart 
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Appendix G. Implementation Plan 
Table G2: Timeline for an EBP Change Project 
PICOT Question: PICOT Question: In neonates with Neonatal Abstinence Syndrome (P), how does adding non-pharmacologic therapies to the 
current medication protocol (I) compared to current medication protocol alone (C) affect the length of stay (O) and length of treatment (O)within one 
quarter (T)? 
Team Leader: Cyndi Kelley 
Team Members: Catrina Mazzella, Beverly McMeans, Veronica Salvador, Suzanna Ice, Cecilia Amar, Racheal Daniel, Kellie Classen, Elaine Simon, 
Annie Ivy, Candace Haney, Yunlin Huang, Nuala Murphy, Sonya Manibusan, Stephanie Schaefer, Kimberly Williams. 
Agency Contact/Mentor Contact Info: Dr. Christina Chan (ChristinaChan@UTSouthwestern.edu and Dr. Venkat Kakkilaya 
(VenkatKakkilaya@UTSouthwestern.edu  
Preliminary 
Checkpoint 
A 
o Select the EBP model 
o Select the change model  
o How it will they guide the 
implementation project  
Notes: John Hopkins 
Nursing Evidence-Based 
Practice Model 
This model was selected due 
to the problem-solving 
approach to clinical 
decision-making.   This 
model is a three-step 
process: 1. Practice question, 
2. Best evidence, 3. 
Translation into practice 
 
Lewin’s Change Theory is 
the basis for this change 
model and breaks down the 
process of change into three 
steps, Unfreeze, Change, and 
Freeze. 
OUTCOMES: Reduce the 
length of stay and length of 
treatment in infants with 
NAS. 
JHNEBP EBP Model  
 
 
 
 
Lewin’s Change Model  
 
 
Preliminary 
Checkpoint 
B 
o Who are the stakeholders for your 
project?  
o Active (on the implementation 
team) & supportive (not on the 
team, but essential to success) 
o Identify project team roles & 
leadership 
o Begin acquisition of any necessary 
approvals for project implementation 
Active stakeholders: 
Cyndi Kelley, Catrina 
Mazzella, Beverly 
McMeans, Veronica 
Salvador, Suzanna Ice, 
Cecilia Amar, Racheal 
Daniel, Kellie Classen, 
Elaine Simon, Annie Ivy, 
All stakeholders aware of 
project  
Roles within project have 
been emailed  
Buy-in has been secured and 
letter of approval from CNO 
has been received.  
Met with nurse scientist.  
Must run project through 
Stakeholder Power Grid 
 
 
Kelley DNP EPIP 
Stakeholder-Register_PowerInterest Grid 11 16 18.xlsx
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and dissemination (e.g., system 
leadership, unit leadership, ethics 
board [IRB]) 
o Consult with Agency Contact/Mentor 
Candace Haney, Yunlin 
Huang 
Passive stakeholders 
Neonatologists, Staff RNs, 
Mother, Infant, CPS 
Faculty mentor: Dr. Ellen 
Fineout-Overholt 
Project Sponsors: Dr. Cole 
Edmonson, Suzanne Murphy 
Nurse Scientist: Dr. June 
Marshall 
Roles include:  
o Neonatologists: Use 
protocol to guide 
treatment of infant  
o Staff RN: Carry out 
actions of protocol as 
directed by Neonatologist 
o Mother – Received 
education from Staff RNs 
on role of rooming in and 
breastfeeding 
o Baby – received treatment 
as mandated by protocol 
o Faculty and Industry 
mentors – provide input 
and guidance during all 
project phases 
o Active stakeholders will 
carry out actions of project 
through each phase 
including education, 
implementation, data 
collection, and evaluation. 
o Passive stake holders will 
administer or receive 
treatment based on update 
protocol 
o Project sponsors will serve 
as mentors, support 
IRB.  Forms must be 
completed (Dr. Marshall 
altered the documents to 
remove research-based 
language to better support 
evidence-based 
implementation project) 
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measures to obtain any 
necessary approvals 
(financial, organizational) 
o CPS – provides social 
service interventions.  As 
assigned to each case, CPS 
worker should receive 
education on protocol by 
staff RN to be considered 
when creating safety plan 
for mother/baby dyad. 
 
Approvals needed/date 
obtained/posted on BB 
HIPAA regs met? 
Checkpoint 
One 
o Hone PICOT question & assure team 
is prepared 
o Build EBP knowledge & skills 
o  Consult with Agency 
Contact/Mentor 
PICOT Question: 
In neonates with Neonatal 
Abstinence Syndrome (P), 
how does adding non-
pharmacologic therapies to 
the current medication 
protocol (I) compared to 
current medication protocol 
alone (C) affect the length of 
stay (O) and length of 
treatment (O)within one 
quarter (T)? 
Stakeholders have been 
notified via presentation 
including PICOT at 
leadership meeting.   
 
 
Checkpoint 
Two 
o Conduct systematic search for 
evidence & retain studies that meet 
criteria for inclusion  
o Connect with librarian 
o Meet with implementation group - 
TEAM BUILD 
o  Consult with Agency 
Contact/Mentor 
Search Results Synopsis Stakeholders readily see 
how PICOT question drove 
systematic search 
Search results (see notes 
column) 
Met with medical librarian 
at THD and librarian at UTT 
 
Team meetings to discuss 
project status and systematic 
search.   
 
Systematic Search:  
 
Evaluation Table:  
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Checkpoint 
Three 
o Critically appraise literature 
(including evaluation, synthesis & 
recommendation) 
o Meet with group to discuss how 
completely evidence answers question 
and drives the project plan;  
o If needed pose follow-up questions 
and re-review the literature as 
necessary 
o  Consult with Agency 
Contact/Mentor 
Recommendation from 
Evidence: Synthesis tables 
lead to the addition of 
breastfeeding and rooming 
in as supportive measures in 
the treatment of infants with 
NAS (BF evidence #1, 2, 4, 
& 5  
RI evidence #1, 2, 3, & 6) 
Team met to discuss 
evidence conclusions.   
Discussed with agency 
mentors and all in 
agreement BR and RI added 
as non-pharm interventions 
to current protocol should be 
included. 
Costs associated with 
adding non-pharm 
interventions to the 
protocol:  Time/Salary for 
education 
Synthesis tables:  
 
 
Checkpoint 
Four 
o Meet with group 
o Summarize evidence with focus on 
implications for practice & conduct 
interviews with content experts as 
necessary to benchmark 
o Begin formulating detailed plan for 
implementation of evidence 
o Include who must know about the 
project, when they will know, how 
they will know 
o  Consult with Agency 
Contact/Mentor 
YOUR PLAN FOR 
IMPLEMENTATION: 
Provide Protocol Specifics, 
Dates & Progress Outcomes: 
 
 
Updated NAS Protocol: 
 
Education Modules: 
1 NAS Education 
Modules - Background and Significance.pptx
 
2 NAS Education 
Modules - Trauma Informed Care.pptx
 
3 NAS Education 
Modules - Addiction.pptx
 
4 NAS Education 
Modules - Finnegan Scoring.pptx
 
5 NAS Education 
Modules - Pharm and Non-Pharm.pptx
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6 NAS Education 
Modules - NAS Treatment Guideline.pptx
 
 
Checkpoint 
Five 
o Define project purpose- connect the 
evidence & the project 
o Define baseline data collection 
source(s) (e.g., existing dataset, 
electronic health record), methods, & 
measures 
o Define post project outcome 
indicators of a successful project 
(process & completion) 
o  Gather valid & reliable outcome 
measures 
o Write data collection protocol 
o Write the project protocol (data 
collection fits in this document) 
o Finalize any necessary approvals for 
project implementation & 
dissemination (e.g.,  system 
leadership, unit leadership, IRB) 
o  Consult with Agency 
Contact/Mentor 
LAUNCH PLAN FOR 
IMPLEMENTATION: 
Provide what is to happen 
when you launch, when and 
how do you know it is 
successful (i.e., protocol 
specific, dates & progress 
outcomes): 
Baseline data will be 
collected using details from 
2017 through current 
(demographic information, 
maternal history, drugs of 
exposure, treatment history, 
onset of symptoms, all 
Finnegan scores, 
escalation/weaning, LOS, 
and LOT) 
Collect financial data and 
review with industry 
mentors 
Present to stakeholders and 
begin meetings with 
committee for education 
planning and 
implementation roll out time 
period.   
Logic model:  
 
Checkpoint 
Six (about 
mid-way) 
o Meet with implementation group 
o Discuss known barriers & facilitators 
of project 
o Discuss strategies for minimizing 
barriers & maximizing facilitators 
o Finalize protocol for implementation 
of evidence, include timeline 
o Identify resources (human, fiscal, & 
other) necessary to complete project 
o Supply Agency Mentor (& Faculty) 
with written IRB approval & 
managerial support 
o Begin work method of dissemination 
of initiation of project & progress to 
 Identify project barriers 
 Identify project 
facilitators 
 Review your timeline – 
dates, measures, plans. 
 Communicate with key 
stakeholders about the 
plan – be creative – 
maybe a newsletter, flyer, 
-- yes, email will do, but 
will it be memorable? 
 Is your data collection 
plan complete? 
 
Data collection plan 
complete. 
Schedule meetings to 
develop treatment guideline.  
Gather group and review 
other facility’s guidelines to 
help shape the document.  
Initial drafts should be 
reviewed, and input sought 
by industry mentor. 
Timeline:  
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date to educate stakeholders about 
project – get help from support staff 
o Include specific plan for how 
evaluation will take place: who, what, 
when, where & how and 
communication mechanisms to 
stakeholders 
o Consult with Agency Contact/Mentor 
Checkpoint 
Seven 
o Meet with implementation group to 
review proposed stakeholder 
dissemination 
o Make final adjustment to 
dissemination plan with support staff 
o Inform stakeholders of start date of 
implementation  
o Address any concerns or questions of 
stakeholders (active & supportive ) 
o  Consult with Agency 
Contact/Mentor 
Review pertinent protocol 
specifics, dates & progress 
outcomes 
: 
Collect data on progress 
outcomes to date and 
include in report 
 
Checkpoint 
Eight 
o LAUNCH EBP implementation 
project 
o Follow project protocol rigorously 
o Collect Baseline Data 
o Deliver Evidence-based Intervention 
o Record process outcomes & lessons 
learned  
o  Consult with Agency 
Contact/Mentor 
Progress Outcomes – are 
things working as you 
thought they would – why or 
why not (reflection) 
Keep a journal of lessons 
learned and your responses 
to them 
 
Checkpoint 
Nine 
o Mid-project: Schedule meeting with 
all key stakeholders to review 
progress outcomes and lessons 
learned (and associated adjustments 
to protocol) to date. 
o Don’t forget to include any issues, 
successes, aha’s, & triumphs of 
project to date. 
o  Consult with Agency 
Contact/Mentor 
Progress Outcomes – are 
things working as you 
thought they would – why or 
why not (reflection) 
Collect data on further 
progress outcomes to date 
and include in report 
Journal lessons learned and 
response. 
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Checkpoint 
Ten 
o Complete final data collection for 
project evaluation 
o Analyze baseline compared to final 
data; create graphics for distribution 
of results 
o Present project progress and 
completion results via poster 
presentation to stakeholders 
o Consult with Agency Contact/Mentor 
& Agency Leadership 
Completion Outcomes data 
collection. 
Analyze the baseline to 
completion data change?  
Did your implementation 
work? 
Evaluate progress outcomes 
-report on success of project 
implementation process 
Completion outcomes 
(analyze pre/post) 
Process outcomes (did 
project process go well/not) 
 
Checkpoint 
Eleven 
o Review project success, including 
progress & completion outcomes, 
lessons learned, and any new 
questions generated from process 
o Consult with Agency Contact/Mentor 
& consider new questions 
Provide Final Evaluation 
Report to Faculty & Agency 
contact, including Next 
Steps for sustainability: 
 Dissemination includes 
making sure that everyone 
is aware of the 
implementation process 
successes, completion 
outcomes and any caveats 
(lessons learned) along 
the way. 
 Dissemination includes 
beyond the organization 
(poster) 
Project Summary 
Poster  
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Appendix H. NAS Guideline 
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Appendix I. Results 
Table I6: Education Module Completion Summary by Role 
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Appendix I. Results 
 
Figure I 1 Pre/Post Education Results by Title 
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Appendix I. Results 
 
Figure I 2 Project Outcome Measure Results by Year – # Cases, ALOS, ALOT  
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Appendix I. Results  
 
 
Figure I 3 Project Outcome Measure by Year – Total Hospital Costs 
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Appendix J. Project Poster 
 
Figure J1 Project Poster  
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Appendix K. Leadership Model 
 
Figure K1 Leadership Model 
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